Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 14/20 | 0.58 |
| ▸ | ACACA | Q13085 | 10/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14380839 | 0.87 | ACACB (0.67) | ACACBACACAPOLBMTNR1AMTNR1B | |
| SCHEMBL6969020 | 0.87 | ACACB (0.67) | ACACBACACAPOLBMTNR1AMTNR1B | |
| SCHEMBL13645881 | 0.82 | ACACB (0.61) | ACACBACACAMTNR1AMTNR1B | |
| SCHEMBL21295116 | 0.82 | ACACB (0.56) | ACACBACACAPOLB | |
| SCHEMBL13645817 | 0.82 | ACACB (0.50) | ACACBACACAPOLBMTNR1AMTNR1B | |
| SCHEMBL29675897 | 0.81 | ACACB (0.60) | ACACBACACAMTNR1AMTNR1B | |
| SCHEMBL18475311 | 0.80 | CASR (0.43) | POLB | |
| SCHEMBL13645850 | 0.79 | ACACB (0.71) | ACACBACACAMTNR1AMTNR1B | |
| SCHEMBL13645876 | 0.79 | ACACB (0.55) | ACACBACACAMTNR1AMTNR1B | |
| SCHEMBL13759315 | 0.78 | GPR139 (0.49) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | ACACB 4200/4885ACACA 3231/4885POLB 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.